| Document |
Document Title |
|
JP2021518347A |
Benzyl derivative compounds with peroxysome growth factor activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and diseases and / or conditions associated with inflammation and / or angiogenesis, par...
|
|
JP6895548B2 |
The present invention relates to method for producing a pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide, having improved moisture stability while maintaining the characteristics, such as the effica...
|
|
JP2021513547A |
Provided are compounds that function as thyroid hormone mimetics, which are useful for treating diseases such as neurodegenerative diseases. Along with pharmaceutical compositions containing such compounds, methods of use and preparation...
|
|
JP6873223B2 |
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cance...
|
|
JP6803138B2 |
A phosphonium compound, an epoxy resin composition, a method of preparing a phosphonium compound, and a semiconductor device encapsulated with the epoxy resin composition, the compound being represented by Formula 1:
|
|
JP2020169193A |
To provide a method for the efficient preparation of 2-substituted-4-amido-1,2,3-triazoles.A method for preparation of compounds of formula 1 (where R2 is an alkyl, aromatic, or heterocyclic group, R3 is an alkyl, aromatic, or heterocycl...
|
|
JP6744669B2 |
Provided is a method for amidating a hydroxy ester compound at a high chemical selectivity. The amidation reaction method for a hydroxy ester compound comprises, in the presence of a catalyst containing a compound of a transition metal o...
|
|
JP6698089B2 |
Disclosed are compounds, for example, compounds of formula I,wherein R, R0, R1-R8, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or cond...
|
|
JP2020514270A |
The present invention discloses a compound represented by the formula (I), which is useful in the treatment of animal respiratory diseases, particularly bovine respiratory diseases or porcine respiratory diseases (BRD and SRD). [Chemical 1]
|
|
JP2019194194A |
To provide a compound for inhibiting HDAC 8.There is provided a compound of the formula 1. In the formula, A is aryl, heteroaryl or the like; X is -C(R)= or -N=; Ris H, halogen, or the like; Y is a bond, -O-, -S-, or the like; Lis a bond...
|
|
JP6600319B2 |
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerati...
|
|
JP2019142777A |
To provide a chemical material that has an effect on a variety of weeds at lower dosage, alleviates problems such as soil contamination and an influence on succeeding crops, has high safety, and is used as an active ingredient of the her...
|
|
JP2019112310A |
To provide a novel agrochemical, particularly a herbicide.The present invention provides an oxime compound represented by formula (1) [where B is B-1 or the like, Q is NOR, A is a hydrogen atom, C-Calkyl or the like, Ris a halogen atom, ...
|
|
JP2019519477A |
The present invention is for treating or preventing novel hydroxamic acid derivatives as inhibitors of meprin β and / or α, pharmaceutical compositions containing such compounds, particularly diseases or conditions associated with mepr...
|
|
JP2019516725A |
A method of preparing an active drug or a salt thereof from a prodrug first compound (1) containing a propargyl group bonded to oxygen that directly or indirectly binds to the active drug, wherein the bond between the propargyl group and...
|
|
JP2019077688A |
To provide substituted hydroxamic acid compounds, and in particular, UDP-3-O-(R-3-hydroxydecanoyl)-N-acetylglucosamine deacetylase (LpxC), and methods of using such compounds to treat Gram-negative bacteria infections.There are disclosed...
|
|
JP6498195B2 |
The present invention relates to hydroxamate compounds and pharmaceutical compositions that are useful for treating and/or preventing metabolic inflammation mediated diseases such as diabetes, obesity, hypertension, dyslipidemia, a neuro...
|
|
JP6491213B2 |
Processes to prepare said compounds and novel intermediates are also claimed. Such compound finds utility in treating neuropathic pain and disorders of the central nervous system.
|
|
JPWO2017170884A1 |
As an intermediate, the general formula [12](In the formula, R1Indicates a methyl group, etc .; R2Indicates a methyl group, etc .; R5Indicates a hydrogen atom or the like. A novel method for producing a hydroxamic acid derivative using t...
|
|
JP6458270B2 |
Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are...
|
|
JP6444487B2 |
Provided is a small molecule compound as represented by structural formula (I). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth ...
|
|
JP6412629B1 |
To provide a radioactive fluorine-containing hydroxamic acid type contrast agent for effectively detecting cerebellar atrophy and a method for producing the same. A radioactive fluorine-containing hydroxamic acid type contrast agent repr...
|
|
JP2018513157A |
The present invention is a heterometal metallacrown compound incorporating Ga (III) and Ln (III) cations with a template ligand such as salicylhydroxamic acid or a derivative thereof, wherein the metallacrown is at least one repeat [ It ...
|
|
JP6327754B2 |
|
|
JP2018021040A |
To provide: a new method for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester; and an intermediate used in such a method.There are provided: N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic aci...
|
|
JP6259814B2 |
A compound represented by general formula (1) (wherein R 1 represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or the like; R 2 represents a hydrogen atom, an optionally substituted C 1-6 alkyl group or the like; R 3 ...
|
|
JP2017214291A |
To provide a novel medical drug that can suppress marrow fiberization associated with myelofibrosis.As the present invention, there are exemplified, for example, (1) a medical drug for suppressing marrow fiberization associated with myel...
|
|
JP6229244B1 |
[Subject] Offer of the manufacturing method of dichloro griot Kishimu which can obtain more safely and more efficiently dichloro griot Kishimu used as the disinfectant for industry, an antiseptic, a slime control agent, etc. [Means for S...
|
|
JP6223336B2 |
Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R1 to R9 have meanings as defined in the Specification, are useful as estro...
|
|
JP6221148B2 |
The present invention relates to a process of making a compound of formula (I): Wherein, R1, R2, R4 and X are as defined herein.
|
|
JP6209541B2 |
This invention relates to novel processes for synthesizing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester and to the compound of formula I below and other intermediates that are used in such processes.
|
|
JP2017525753A |
Compounds that regulate the redox enzyme indoleamine 2,3-dioxygenase and compositions containing the compounds are described herein. The use of the compounds and compositions for the treatment and / or prevention of a wide variety of dis...
|
|
JP2017512187A |
The present invention relates to precursor materials that can be decomposed to form semiconductors and metal oxides, or more generally materials for electronic components. The precursor comprises a metal complex of a hydroxamato ligand. ...
|
|
JP2017511402A |
This application manufactures perfume raw materials, perfume delivery systems, and consumer products including this type of perfume raw material and / or this type of perfume delivery system, as well as such perfume raw materials, perfum...
|
|
JP6109821B2 |
The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for tr...
|
|
JPWO2015056799A1 |
An object of the present invention is to provide a novel compound which has strong antibacterial activity against gram-negative bacteria such as Pseudomonas aeruginosa and drug-resistant bacteria thereof and is useful as a pharmaceutical...
|
|
JP6087386B2 |
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for det...
|
|
JP6061897B2 |
The present invention relates to tetracycline derivatives, and in particular to sancycline derivatives substituted at their 7-position by a five-membered heterocyclic ring, for use in the treatment of bacterial, viral and/or parasitic in...
|
|
JP6063393B2 |
[Problem] The present invention provides a glyoxime derivative displaying excellent pesticidal effect or a salt thereof and a pesticide containing the same as an active ingredient. [Solution] This pesticide is characterized by containing...
|
|
JP2016210682A |
To provide a novel compound that shows strong antibacterial activity on a Gram-negative bacterium such as Pseudomonas aeruginosa and a drug-resistant bacterium thereof, and is useful as a pharmaceutical.The present invention provides N-h...
|
|
JP2016210683A |
To provide a novel compound that shows strong antibacterial activity on a Gram-negative bacterium such as Pseudomonas aeruginosa and a drug-resistant bacterium thereof, and is useful as a pharmaceutical.The present invention provides N-h...
|
|
JP6037392B2 |
|
|
JP2016199499A |
To provide: stable crystal forms of compounds having (2S)-2-methylamino-N-hydroxy-N',2-dimethylpropanediamide as drug substances; and production methods of the crystal forms.The solutions include B-type crystals of (2S)-2-[{4-[4-(1-amino...
|
|
JP2016530273A |
Among other things, compounds and methods for treating cancer by inhibiting HDAC8 are provided herein. Methods of treating cancer are also provided herein. In one aspect, it is a method of treating a cancer in a subject in need of treatm...
|
|
JP2016164159A |
To provide compounds that are novel modulators, e.g., activators or agonists, of the human calcium sensing receptor (CaSR) and effective in treatment of chronic kidney disease and osteoporosis.The invention provides a compound represente...
|
|
JP5982705B2 |
Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the SIP receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment...
|
|
JP5946288B2 |
|
|
JP5940984B2 |
The present invention relates to novel "reverse amide" compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
|
|
JP5934184B2 |
Tranylcypromine derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of histone demethylases LSD1 and LSD2, such as the diseases characterized ...
|
|
JP2016094401A |
To provide: compounds used for cardiovascular diseases, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and conditions responsive to nitroxyl therapy; pharmaceutical compositions and kits comprising the compounds;...
|
